The POSITIVE study of Ilumetri significantly improved wellbeing in patients with moderate-to-severe plaque psoriasis. - Almirall SA

The preliminary analysis also showed that tildrakizumab significantly improved skin symptoms and patients’ health-related quality of life (HRQoL), with high rates of treatment satisfaction in patients with moderate-to severe plaque psoriasis after 28 weeks in a real-world setting, with no new safety signals and a reassuring safety profile consistent with randomized clinical trials (RCT). The results also demonstrated for the first time that the wellbeing level at baseline of patients with moderate-to-severe plaque psoriasis was comparable to the wellbeing level found in other diseases such as breast cancer.

The POSITIVE study is the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint using the WHO-5. The 5item World Health Organization Wellbeing Index is a widely used questionnaire that assesses health-related subjective psychological wellbeing in a variety of chronic diseases. In addition to evaluating the severity of psoriasis, there is a need for a holistic, person-centred approach to the assessment of wellbeing that has never before been measured in a robust prospective study. The results of this study could potentially be added to the available psoriasis evaluation methods and provide dermatologists with new tools to improve their patients’ wellbeing by enhancing patient-clinician relationships.

Psoriasis affects an estimated 60 million people worldwide, and the severity of psoriasis is profound, involving both a physical and psychological burden. Almost 77% of patients believe that psoriasis negatively affects their normal daily activities (personal, social, and work life) and wellbeing. In addition, psoriasis can significantly affect the general wellbeing of their families and physicians' satisfaction.